Amyotrophic lateral sclerosis (ALS)

Researchers are testing whether transcranial static magnetic field stimulation (tSMS), delivered via a helmet worn at home, can slow the progression of amyotrophic lateral sclerosis (ALS). About 60 adults with recent-onset ALS will use the device for two daily sessions of 120 min…

This Phase 2 trial tests whether a combination of over-the-counter antioxidants, including vitamin E and N-acetylcysteine, can slow the progression of amyotrophic lateral sclerosis (ALS). Researchers will give high doses of these supplements to 21 adults with ALS and measure chan…

This trial tests a personalized drug called nL-TARDB-006, designed for people with ALS caused by a specific genetic mutation in the TARDBP gene. The drug is an antisense oligonucleotide, which aims to target the genetic cause of the disease. Six participants will receive the trea…

This clinical trial is testing an oral drug called NUZ-001 in 160 people with ALS. Participants take the drug or a placebo daily for 36 weeks. The study measures how the disease progresses using a scale of physical function and survival. The goal is to see if NUZ-001 can slow ALS…

This study tests a personalized antisense oligonucleotide drug designed for a single person with ALS caused by a specific TARDBP gene mutation. The drug aims to reduce harmful TDP-43 protein and slow disease progression. The participant's clinical function, survival, and biomarke…

This phase 2 trial tests whether the experimental drug VHB937 can slow the decline in function and delay the need for breathing support in people with early-stage ALS. About 251 participants will receive either VHB937 or a placebo for 40 weeks, followed by an open-label extension…

This early-stage trial tests a single injection of RJK002, a gene therapy, into the spinal fluid of 9 people with ALS. The main goal is to see if it is safe and to find the best dose for future studies. Researchers will also track changes in daily function, but the trial is too s…

This pilot study tests whether using a robotic glove for 20 minutes a day, 5 days a week, can improve quality of life, grip strength, and fine motor control in people with ALS. Five participants will use the glove at home over 8 weeks, with some in-person and telehealth check-ins…

This study uses advanced MRI scans and genetic tests to track how neurodegenerative diseases like frontotemporal dementia and ALS spread across the brain's network. Researchers will follow 645 participants, including patients, family members, and healthy controls, for up to 2 yea…